{"id":"W4318693852","doi":"10.1200/jco.22.02186","title":"Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":389,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; AstraZeneca","keywords":"Medicine; Afatinib; Clinical endpoint; Internal medicine; Oncology; Osimertinib; Lung cancer; Hazard ratio; Cancer; Clinical trial; Stage (stratigraphy); Adenocarcinoma; Confidence interval; Erlotinib; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"}],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006126831,0.0002625988,0.002944269,0.0001600858,0.0001926824,0.00003010446,0.0003083349,0.0004215178,0.0002928297],"category_scores_gemma":[0.008428186,0.0001429454,0.001101028,0.0004956573,0.0002628464,0.00009924053,0.00006753308,0.0009711326,0.00001635065],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003024891,"about_ca_system_score_gemma":0.004966045,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008957332,"about_ca_topic_score_gemma":0.0002996278,"domain_scores_codex":[0.9930717,0.001055976,0.00457662,0.0003915923,0.0004511279,0.0004529793],"domain_scores_gemma":[0.9798626,0.01492204,0.003408493,0.0003795526,0.0009883463,0.0004390093],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8970804,0.001801553,0.0001590921,0.00001797819,0.003186971,0.0004542609,0.0009144054,0.0001281759,0.0005494182,0.000009812089,0.07624538,0.01945257],"study_design_scores_gemma":[0.9135895,0.008790943,0.001034784,0.000161864,0.00575361,0.00001030015,0.0004302665,0.007671444,0.0003718648,0.0001036582,0.06194002,0.0001416835],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9675907,0.0008045755,0.0004821353,0.02085096,0.00436549,0.004163289,0.0007368292,0.00005984211,0.0009462112],"genre_scores_gemma":[0.9824337,0.002450912,0.001390802,0.002976971,0.003945875,0.0003222931,0.0009439206,0.00006423175,0.00547129],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01931089,"threshold_uncertainty_score":0.9999242,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1084029731460099,"score_gpt":0.5189698770640995,"score_spread":0.4105669039180896,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}